Edesa Biotech, Inc.
EDSAHealthcare|Biotechnology|CA
$2.14
+0.01 (+0.47%)
DCF Value
$2.00
Tangible Book / Share
$0.77
Cash / Share
$1.15
About
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Stock Price
+25.9%(1Y)
1M
-41.5%
3M
-59.4%
6M
-86.9%
YTD
+50.7%
1Y
+23.7%
3Y
-31.6%
5Y
-96.0%
Pipeline Summary
7 total trials0
Phase 1
7
Phase 2
1
Phase 3
0
Phase 4
Recruiting: 5Terminated: 1Completed: 1
Active Trials (5)
A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo
NCT07889492Non-Segmental Vitiligo (NSV)
Phase 2Recruiting
Enrollment: 80 participants
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
NCT06701656Acute Respiratory Distress Syndrome (ARDS)
Phase 2Recruiting
Enrollment: 200 participants
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
NCT06701682Acute Respiratory Distress Syndrome (ARDS)
Phase 2Recruiting
Enrollment: 200 participants
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
NCT06703073Acute Respiratory Distress Syndrome (ARDS)
Phase 2Recruiting
Enrollment: 600 participants
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
NCT06701669Acute Respiratory Distress Syndrome (ARDS)
Phase 2Recruiting
Enrollment: 200 participants
Key Facts
Market Cap$20.6M
Employees17 (+6% YoY)
CEOPardeep Nijhawan
IPO DateJun 21, 2010
Beta1.06
52-Week Range$0.72 – $20.32
Avg Volume58,341
ExchangeNASDAQ
Websiteedesabiotech.com
Ownership
Float79.7%
Shares Outstanding9.6M
Recent Insider Trades
Nijhawan PardeepAWARD
Nov 4, 202618,677 shares
Nijhawan PardeepAWARD
Oct 28, 202627,602 shares
Nijhawan PardeepAWARD
Oct 5, 20266,893 shares
Nijhawan PardeepAWARD
Sep 1, 20265,714 shares
Nijhawan PardeepAWARD
Aug 3, 20265,324 shares
Peers
Recent News
Edesa Biotech to Present at Guggenheim Healthcare Innovation Conference
Nov 4, 2026 · globenewswire.com
Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study
Oct 15, 2026 · globenewswire.com
Edesa Biotech Announces Pricing of $25.0 Million Public Offering
Aug 19, 2026 · globenewswire.com
Edesa Biotech Announces Proposed Public Offering
Aug 19, 2026 · globenewswire.com
Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
Aug 13, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:07 AM